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Abstract 
In clinical practice, caregivers of children with phenylketonuria (PKU) report 
that their children have breath malodour. This might be linked to the regular 
consumption of low phenylalanine (Phe)/Phe-free protein substitutes (PS), 
which are an essential component of a low-Phe diet. Oral malodour can 
negatively affect interpersonal communication, lead to bullying, low self-
esteem and social isolation. In this longitudinal cross-over study, exhaled 
volatile organic compounds (VOCs) were measured using gas 
chromatography – ion mobility spectrometry (GC-IMS). 40 children (20 PKU, 
20 controls) were recruited. Subjects with PKU took either L-Amino Acid (L-
AA) or Casein Glycomacropeptide (CGMP-AA) exclusively for 1 week, in a 
randomised order. On the 7th day, 7 exhaled breath samples were collected 
over a 10-hr period. Subjects then transferred to the other PS for a week and 
on day 7, provided 7 further breath samples. All subjects had a standardised 
menu using low-Phe food alternatives and all food intake was measured and 
recorded. In the PKU group, the aim was to collect samples 30-min after 
consuming PS. In 3 subjects, breath was collected 5-min post-PS 
consumption. Fasted L-AA and CGMP-AA breath samples contained a 
similar number of VOC peaks (10-12) as controls. Longitudinal breath testing 
results demonstrate that there was no significant difference in the number of 
exhaled VOCs, comparing L-AA or CGMP-AA with controls, or between PS 
(12-18 VOC peaks). Breath analysed immediately after consumption of PS 
(n=3) showed an immediate increase in the number of VOC peaks (25-30), 
but these were no longer detectable at 30-min post-consumption. This 
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suggests PS have a transient effect on exhaled breath. Measurements taken 
30-min after consuming L-AA or CGMP-AA were not significantly different to 
controls. This indicates that timing food and drinks with PS consumption may 
be a potential solution for carers to reduce or eliminate unpleasant PS-related 
breath odours.  
Keywords: Phenylketonuria (PKU); glycomacropeptide; PKU supplements; 
breath analysis; breath malodour; GC-IMS; volatile organic compounds 
(VOCs) 
1 Introduction 
Phenylketonuria (PKU) is an inherited metabolic disorder, caused by a 
deficiency in the enzyme phenylalanine hydroxylase (PAH), which is 
responsible for converting the amino acid phenylalanine (Phe) into tyrosine. 
This metabolic disruption causes Phe levels to accumulate in blood, which if 
untreated, causes neurotoxicity [1] leading to severe and irreversible 
neurological impairments [2]. PKU has been reported in all ethnic groups, 
affecting males and females in similar numbers. Incidence rates are around 1 
in every 10,000 births but with a high prevalence in Turkey, Poland and Ireland 
[3]. In the UK, infants with PKU are detected by new-born screening [4]. While 
there is no cure for PKU, effective management of the condition is achieved 
through dietary restriction of Phe (in the form of a strict low-protein diet) and 
supplementation with Phe-free protein substitutes (PS) [5]. PS are essential, 
supplying adequate nitrogen for growth, suppressing blood Phe 
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concentrations, and most will provide comprehensive vitamin and mineral 
supplementation meeting age appropriate requirements. 
Most children with PKU tolerate <10g/day natural protein. This means that 
high protein foods are avoided with a controlled intake of some vegetables and 
cereals and children must eat different foods from their friends, compromising 
normal socialisation. They are usually recommended to take PS 3 times daily 
with meals. While there have been significant improvements in the taste, 
appearance and presentation of PS [6], overall PS tastes unpleasant and 
patients often associate intake with bad breath. This is a concern of parents 
and caregivers, since oral malodour can result in psychological distress, 
interfere with social interactions, lower self-esteem and body-image [7]. Breath 
malodour in PKU has received little clinical or research attention, and it is 
unknown if this is an issue more common in PKU than a healthy population.  
This study focuses on 2 types of PS; Phe-free L-amino acids (L-AA) and 
low-Phe casein glycomacropeptide (CGMP-AA). Conventional L-AA consist of 
single amino acids and have a characteristic odour associated with their pure 
amino acid composition. Casein glycomacropeptide is a peptide, derived from 
the whey fraction during the cheese manufacturing process. It is naturally low 
in phenylalanine and after the addition of some essential amino acids, has 
been adapted for use as a PS in PKU. CGMP-AA has a different composition 
from L-AA PS, being made of 60% peptide and 40% L-AA. In PKU, no studies 
have compared L-AA with CGMP-AA and reported impact on breath malodour. 
It is suggested that CGMP-AA is associated with less oral malodour. 
Since there is limited research, the authors propose 3 possible causes for 
PKU-associated breath malodour: (1) residue from the PS in the oral cavity 
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leads to a temporary change in breath composition (i.e. breath smells like the 
PS); (2) residue and regular replenishment of sulphur-containing amino acids 
from the PS (such as cystine and methionine) serve as a substrate for bacterial 
degradation in the oral cavity [8] resulting in the release of volatile sulphur 
compounds (VSCs) such as hydrogen sulphide, methyl mercaptan, and 
dimethyl sulphide (DMS), which are typically associated with halitosis [9]; and 
(3) modifications to the exhaled breath composition of subjects with PKU is 
caused by changes in metabolism or the gut microbiota due to their low-protein 
diet [10], resulting in oral malodour. These factors are not necessarily mutually 
exclusive and could be produced by a combination of these effects.  
Currently, 3 methods for measuring oral malodour are available, including: 
organoleptic measurement, sulphide monitors and gas chromatography – 
flame photometric detector (GC-FPD) [11]. The organoleptic method is 
generally considered the gold standard halitosis test, and involves assessing 
oral malodour, as perceived by the human nose of a trained investigator [12]. 
However, this method is expensive (requiring a highly trained professional), 
subjective (cannot accurately quantify the oral malodour level) and is 
unsuitable for testing large study groups. Portable commercial instruments 
such as the OralChroma (Nissha FIS, Osaka, Japan) and Halimeter (Interscan 
Cor., Simi Valley, CA, USA) provide a relatively inexpensive and easy-to-use 
alternative to quantify odour levels. The disadvantages of these devices are 
that they can only measure VSCs with relative concentration measurements 
and cannot provide chemical identification of other volatile organic compounds 
(VOCs) in exhaled breath [13]. GC-FPD is a reliable, objective and 
reproducible method of quantifying breath contents. However, these 
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instruments are bulky, expensive and require trained operators [14]. In recent 
years, alternative GC-based technologies, such as combining GC with ion-
mobility spectrometry (collectively known as GC-IMS), have produced portable 
analysers for exhaled breath, which can measure VOCs in the low parts-per-
billion (ppb) range and are suitable for sampling vulnerable subjects, including 
children.  
Therefore, in a collaborative research effort, undertaken by Birmingham 
Children's Hospital, the University of Warwick and University Hospitals 
Coventry and Warwickshire, this study aims to investigate the phenomenon of 
paediatric PKU breath malodour by analysing exhaled breath using GC-IMS 
technology.  
2 Materials and methods  
2.1 Subjects 
Forty children (20 PKU, 20 healthy controls) were recruited for this 
longitudinal cross-over pilot study. This study received ethical approval (IRAS 
ref: 211894) and was conducted in accordance with the Declaration of 
Helsinki. Participants were recruited to create a balanced cohort (gender, age, 
and ethnically matched). The median age was 11 years (range 7-15.5 years), 
including 18 males and 22 females. The Phe concentrations of subjects with 
PKU were measured by weekly blood spots 12 months prior to starting the 
study. Median Phe concentrations for children ≤12 years (n=17) was 270 
μmol/L (range 150-360 μmol/L), and children >12 years (n=3) was 330 μmol/L 
(range 315-350 μmol/L). Both these groups show excellent Phe control within 
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the European target recommendations [15]. An overview of the demographic 
data for the study is shown in Table 1. 
Table 1. PKU breath study demographic data of subjects. 
Parameter Subjects with PKU (n=20) Controls (n=20)  
Age (SD) 10.5 (2.5) 10.6 (2.5) 
Gender ratio M:F 9:11 9:11 
Siblings (Twins) 3 (1) 4 (0) 
Regular medication 
(No. of subjects) 
Ritalin (1)  
Neurotransmitter medication (1) 
N/A 
 
Eight sets of siblings were involved in this study; 4 sets in both groups and 
1 set provided a control and a child with PKU. Recruiting siblings can reduce 
the possible effects of confounding factors, such as lifestyle and environment 
[16]. Confounding factors can be accounted for in the design-stage by 
recruiting a balanced cohort and in the analysis stage by separately 
investigating factors, such as age and gender. For these purposes, age and 
gender groups were defined as [≤10 vs >10 years] and [male vs female], 
respectively. The confounding factor groups are shown in Table 2.  
Table 2. Confounding factor groups. 
Factor Groups PKU Controls Total 
Age 
≤10 years 10 10 20 
>10 years 10 10 20 
Gender 
Male 9 9 18 
Female 11 11 22 
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2.2 Study Design 
To better understand the effects of paediatric PKU breath malodour, the 
recruited subjects were asked to complete a questionnaire relating to how they 
perceive their breath. Subjects with PKU took all their PS requirement from 
either L-AA or CGMP-AA exclusively for 7 days, in a randomised order. On 
the 7th day exhaled breath samples were collected over a 10 hour period. The 
subjects arrived fasted and samples were collected first thing, post-morning 
meal, pre- and post-midday and evening meals, and an afternoon sample 
taken at a standard time. Subjects with PKU then transferred to the other PS 
for 7 days and on day 7, provided 7 further breath samples as before. When 
randomised to L-AA, 17 children were on liquid and 3 on powdered products. 
The liquid L-AA PS were: PKU Lophlex LQ juicy berry n=3, (Nutricia Ltd), PKU 
Cooler red n=12, PKU Cooler Air red n=2, (Vitaflo, Liverpool, UK). The flavours 
of the L-AA powder PS were: PKU express raspberry n=1, PKU gel raspberry 
n=1, (Vitaflo, Liverpool, UK), PKU First Spoon unflavoured n=1 (Nutricia Ltd). 
They were all reconstituted with water. CGMP-AA was also a powdered PS, 
available in vanilla n=2 and berry n=18 flavours (Vitaflo Ltd, Liverpool, UK) and 
was reconstituted with water. 
For the first breath sample (before morning meal) all children attended the 
research unit without brushing their teeth. Breath samples were collected in a 
staggered timetable to maintain standard interval times between samples for 
all subjects. A maximum of 4 subjects were sampled each day, including 
control, L-AA and CGMP-AA subjects on most days. All subjects consumed a 
standardised menu on the days of breath sampling using low-Phe alternatives, 
e.g. low-protein pasta for subjects with PKU and regular pasta for controls. All 
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food intake was measured and recorded. The cross-over study design and 
staggered timetable are shown in Figure 1 and Appendix A, respectively.  
 
Figure 1. Longitudinal cross-over study design: subjects with PKU consumed L-AA 
or CGMP-AA exclusively, by random order for 7 days, and on day 7, provided 7 
breath samples. Subjects with PKU then transferred to the other PS for 7 days and 
provided 7 further breath samples on day 7. 
 
In the PKU group, the aim was to collect samples 30 minutes after 
consuming the PS to allow subjects to digest and metabolise their meals and 
PS. This enabled measurements in potential changes in exhaled breath 
composition related to the metabolism of PS (i.e. pharmacokinetic changes), 
instead of residue from the PS.  
2.3 Gas Chromatography – Ion Mobility Spectrometry 
This study utilised a commercially-available, gas chromatography – ion 
mobility spectrometry (GC-IMS) instrument (G.A.S. BreathSpec, Dortmund, 
Germany). This technology uses GC as a pre-separator, followed by a drift-
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tube IMS detector. The BreathSpec GC-IMS was equipped with a MXT-200 
midpolarity column (Thames Restek, Saunderton, UK) and fitted with a 
circulator gas flow unit (G.A.S. CGFU, Dortmund, Germany). This unit 
recirculated and filtered the air and allowed the unit to operate without the 
need of an external gas supply. When the breath sample was introduced to 
the GC, chemical interactions with the column cause individual compounds to 
elute at different times – known as the retention time. This stage was followed 
by the IMS detector, where the pre-separated analytes were ionised and 
injected into a drift tube. The ions drifted against a buffer gas, under influence 
of a uniform electric field (400 V/cm). This enabled ions to achieve different 
velocities, inversely proportional to their size, mass and charge [17]. They 
were then collected on a Faraday plate, to provide a time-dependent signal 
corresponding with ion mobility. The buffer gas flow rate was 150 ml/min and 
carrier flow rate through the instrument was 15 ml/min, while the sample was 
being introduced. The carrier flow rate was then ramped to 50ml/min over the 
11-minute measurement time. The temperatures of the GC column and IMS 
were set to 45°C. The device can measure substances down to the low ppb 
range, depending on the proton affinity of the compound. The instrument was 
suitable for a clinical setting and was placed on a work surface (dimensions: 
45 x 50 x 30 cm; mass: 20 kg).  
2.4 Breath Sampling 
The BreathSpec instrument collects end-tidal breath using an integrated 
sampling system. Subjects were provided with a disposable polypropylene 
mouthpiece (G.A.S., Dortmund, Germany), which attached to a holder 
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(connected to the front-panel of the instrument). A new mouthpiece was 
provided for each sample. The mouthpiece is a tapered and open-ended tube, 
with a one-way valve. As the subject exhales through the tube, air is displaced, 
which separates dead-space from end-tidal breath. This portion of exhalate is 
pulled into the 10mL sample loop, prior to being introduced to the GC column. 
The transfer tubing between the mouthpiece holder and instrument/sample 
loop was heated, with a temperature set to 45°C. The sampling procedure only 
required around 4 seconds of exhaled breath. Subjects were not required to 
exhale until their lungs were as empty as possible; instead, sampling only 
required a single normal breath. This procedure improved reproducibility and 
was appropriate for paediatric subjects.  
2.5 Data Analysis 
A typical output response (chromatogram) from the GC-IMS is shown in 
Figure 2; specifically, a fasted sample from a control subject. The 
chromatogram is represented as a topographic map, whereby each data point 
was characterised by the retention time in the chromatographic column (in 
seconds), the drift time (in milliseconds) and the intensity of the ion current 
signal (in volts), as indicated by colour. The reactant ion peak (RIP) refers to 
the constant peak in the spectrum that results from the carrier gas being 
always present in the measurement process. This peak can be used to align 
samples for data analysis. As a result, the drift time is represented as a RIP 
relative value. Laboratory Analytical Viewer (LAV) software (v2.2.1, G.A.S., 
Germany) was used to analyse chromatograms.  
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Figure 2. Typical GC-IMS BreathSpec output chromatogram (control subject). 
 
For data analysis, a custom program was written in MATLAB (R2018b, 
MathWorks, Natick, MA, USA) to detect, count and extract VOC information. 
This data analysis approach attempts to represent breath samples as VOC 
‘fingerprints’ by quantifying the number and types of endogenous VOCs 
(compounds that originate from within the body). This method has been 
previously used to demonstrate that patients with Alzheimer’s disease have 
different exhaled breath VOC fingerprints than healthy controls [18]. The first 
step involves a pre-processing stage. The aim of which was to remove the 
background (that contains no useful information). A typical GC-IMS dataset 
contains 11 million data points. The individual regions of high intensity, which 
correspond to individual VOC peaks, are thus made up of tens of single data 
points. Since we were only interested in these areas, we could remove the 
background by setting a static threshold. The remaining clusters of non-zero 
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data points can then be considered as individual VOC peaks and totalled. In 
addition, their locations and maximum intensities can be extracted. Maximum 
peak intensities were selected, as we are able to correspond this with the 
abundance of the compound and it is independent of the applied background 
threshold. Using the locations of the VOC peaks, GC-IMS Library Search 
software (v1.0.1, G.A.S., Dortmund, Germany) was used to identify the 
compounds, based on gas chromatographic retention times and ion mobility 
drift times. These were linked to a NIST database, which included 400,000 
annotated retention indices and an estimated 83,000 compounds entries [19]. 
Some common breath VOCs have been labelled in Figure 2.  
2.6 Quality Assurance and Control 
For quality assurance, the position and quality of the RIP on the GC-IMS 
was regularly checked for signs of contamination. Samples were collected in 
the same setting, by the same operator, throughout the study. This ensured 
consistent sampling procedures since the collection process was manually 
triggered by the operator, while the subject exhaled through the mouthpiece. 
Additional quality control procedures were implemented. This involved 
collecting 4 room air samples at suitable intervals between breath samples 
(8:00, 11:00, 15:15 and 18:45) to monitor changes in ambient air and identify 
exogenous VOCs (compounds that do not originate from within the body).   
To match the GC-IMS Library Search software with the equipped column, 
the GC-IMS instrument was normalised using a standard ketone mix (2-
butanone, 2-pentanone, 2-hexanone, 2-heptanone, 2-octanone). The 
locations of common breath VOCs, such as acetone, 2-butanone, pentanal, 
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hexanal and 1-propanol were also verified using chemical standards. The 
locations of other compounds, such as dimethyl sulphide and limonene were 
identified using the GCxIMS Library Search software. In addition to 
normalising the column for compound identification, it is possible to develop 
quantification curves for some VOCs. This was achieved using a dilution 
series of the target compound to generate a calibration function, which allows 
the voltage signal from the GC-IMS output to be converted into ppb 
concentrations. 
3 Results 
3.1. Questionnaire Responses 
The questionnaire responses are shown in Figures 3 to 8. The results 
indicate that 50% of subjects with PKU dislike or strongly dislike the taste of 
L-AA, compared to 35% with CGMP-AA (Figure 3). Subjects with PKU worry 
more about their breath smelling when consuming L-AA, over CGMP-AA 
(Figure 4 and Figure 8). Controls stated that they worried little or not at all 
about their breath and that others do not comment on their breath (Figure 4 
and Figure 5). This suggests that the problem is associated with PS 
consumption. While most subjects (controls and subjects with PKU) noticed 
their breath smelling when fasting in the morning, subjects with PKU also 
observed their breath odour in the afternoon and after consuming PS (Figure 
6). A limited number of subjects from both PS groups worried their breath smell 
might affect friendships (Figure 7). The questionnaire results indicate that 
subjects with PKU experience breath malodour in greater numbers than 
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controls and that these subjects notice their breath smelling more when 
consuming L-AA, compared to CGMP-AA.  
Descriptive statistics were applied to the questionnaire results, using one-
way ANOVA analysis and Wilcoxon matched t-test. A significant difference 
between the L-AA compared to the CGMP-AA and control groups was evident 
when children were asked ‘Q2: Do you worry about your breath smelling?’ (p 
= 0.02), ‘Q3: Do others notice/comment your breath smells?’ (p = 0.03), ‘Q5: 
Does your breath affect your friendships?’ (p = 0.04), ‘Q6+7: Do you notice 
your breath smells more with L-AA than CGMP-AA, or CGMP-AA than L-AA?’ 
(p < 0.0001). 
 
 
Figure 3. Questionnaire - Responses to Question 1 (Q1): Do you like/dislike the 
taste of your L-AA or CGMP-AA supplements? 
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Figure 4. Questionnaire - Responses to Question 2 (Q2): Do you worry about your 
breath smelling? 
 
Figure 5. Questionnaire - Responses to Question 3 (Q3): Do others 
notice/comment your breath smells? 
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Figure 6. Questionnaire - Responses to Question 4 (Q4): When does your breath 
smell more? 
 
 
Figure 7. Questionnaire - Responses to Question 5 (Q5): Does your breath affect 
your friendships? 
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Figure 8. Questionnaire - Responses to Questions 6 and 7 (Q6+7): Do you notice 
your breath smells more with L-AA than CGMP-AA (blue) or CGMP-AA than L-AA 
(red)? 
 
3.2. Headspace Gas and Exhaled Breath Outputs 
To demonstrate that the BreathSpec GC-IMS could measure VOCs from 
the PS, analysis was conducted of the headspace gas generated from heating 
up a small portion (5mL) to 40°C (DB-2D Dri-Block, Techne, Stone, UK) in a 
20mL glass vial, for 10 minutes. To illustrate the change in the GC-IMS output, 
an empty vial was also analysed.  
For comparison, the exhaled breath of 1 subject with PKU was analysed, 
5 minutes after consuming the PS. To demonstrate the change in the GC-IMS 
output, the exhaled breath of the same subject was analysed in a fasted state, 
30 minutes after consuming the PS, and 105 minutes after consuming the PS. 
The results for L-AA and CGMP-AA are shown in Figures 9 and 10, 
respectively.  
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Figure 9. L-AA: (a) Empty vial; (b) L-AA headspace gas; (c) Subject with PKU fasted exhaled breath; (d) Subject with PKU exhaled breath 5-
min post-consumption of L-AA; (e) Subject with PKU exhaled breath 30-min post-consumption of L-AA; (f) Subject with PKU exhaled breath 
105-min post-consumption of L-AA. 
(a) Empty Vial 
(6 VOC Peaks) 
(b) L-AA Headspace 
(75 VOC Peaks) 
(c) L-AA Fasted Breath 
(9 VOC Peaks) 
(d) L-AA Breath 5-min Post-Consumption 
(25 VOC Peaks) 
(f) L-AA Breath 105-min Post-Consumption 
(14 VOC Peaks) 
(e) L-AA Breath 30-min Post-Consumption 
(16 VOC Peaks) 
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Figure 10. CGMP-AA: (a) Empty vial; (b) CGMP-AA headspace gas; (c) Subject with PKU fasted exhaled breath; (d) Subject with PKU 
exhaled breath post-consumption of CGMP-AA; (e) Subject with PKU exhaled breath 30-min post-consumption of CGMP-AA; (f) Subject with 
PKU exhaled breath 105-min post-consumption of CGMP-AA. 
(a) Empty Vial 
(6 VOC Peaks) 
(b) CGMP-AA Headspace 
(140 VOC Peaks) 
(c) CGMP-AA Fasted Breath 
(11 VOC Peaks) 
(d) CGMP-AA Breath 5-min Post-Consumption 
(30 VOC Peaks) 
(f) CGMP-AA Breath 105-min Post-Consumption 
(13 VOC Peaks) 
(e) CGMP-AA Breath 30-min Post-Consumption 
(11 VOC Peaks) 
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The VOC analysis program detected >75 VOC peaks in the headspace 
gas of supplement L-AA, compared to 25 in exhaled breath from a subject with 
PKU, 5 minutes post-consumption of PS. Supplement CGMP-AA had >140 
VOC peaks in headspace gas and 30 VOC peaks 5 minutes post-consumption 
of PS. By comparison, there were 9 and 11 VOC peaks in the fasted breath 
samples of the same subject, respectively. The number of VOC peaks in 
samples collected 30- and 105-minutes post-consumption of either PS (11-16 
VOC peaks) are significantly lower than in samples collected 5 minutes post-
consumption. The extracted VOC peak locations from the PS established a 
strong alignment between VOCs found in the headspace gas and exhaled 
breath, shortly after consumption.  
3.3. Longitudinal Breath Samples 
Figure 11 shows the longitudinal trends of the number of VOC peaks in 
the exhaled breath samples of controls, and subjects with PKU consuming L-
AA and CGMP-AA, across all 7 sampling intervals. The plot represents mean 
values, with standard error whiskers.  
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Figure 11. Number of VOC peaks by intervention groups. 
 
Closer examination of the fasted sampling interval demonstrated that the 
number of VOC peaks for all groups start at similar levels. A box plot of the 
number of VOC peaks for the fasted samples is given in Figure 12. This 
demonstrated that the average number of VOC peaks in controls was slightly 
lower than L-AA and CGMP-AA, but not significantly different. CGMP-AA was 
associated with the greatest variance.  
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Figure 12. Box plot for number of VOC peaks from fasted sampling interval. 
 
In addition to monitoring the number of VOCs peaks, it was possible to 
track the intensity of specific VOCs, such as acetone, dimethyl sulphide and 
2-butanone (Figures 13-15, respectively). Dimethyl sulphide was of particular 
interest, since it is a compound typically associated with halitosis.   
 
 
Figure 13. Acetone intensity changes by intervention groups. 
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Figure 14. Dimethyl sulphide intensity changes by intervention groups. 
 
 
Figure 15. 2-butanone intensity/concentration changes by intervention groups. 
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The intensity trends shown in Figures 13 and 14 indicate that acetone and 
dimethyl sulphide exhibit similar trends across all groups. The intensity trends 
of 2-butanone (Figure 15) show some differences between subjects with PKU 
and controls. The post-morning meal (post-fasted) sample is associated with 
a sharp increase in 2-butanone for subjects with PKU (both L-AA and CGMP-
AA). To better characterise this behaviour, the quantification procedure 
described in Section 2.6 was completed for 2-butanone to convert voltage 
signals from the GC-IMS output into ppb concentrations. The quantification 
model indicates that the concentration of 2-butanone in the post-fasted 
samples for subjects with PKU was around 3.9 ppb, compared to 2.0 ppb for 
controls. Subsequent samples are comparable in intensity (around 3.0 ppb) 
for all groups and follow similar increasing trends for the rest of the day. 
3.4. Confounding Factors 
The analysis in Figure 11 was repeated after categorising the subjects 
based on confounding factor groups, instead of intervention groups, e.g. 
younger vs older subjects, instead of controls vs L-AA vs CGMP-AA. The 
longitudinal trends of the number of VOC peaks in exhaled breath samples, 
based on age and gender, are shown in Figures 16 and 17, respectively.  
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Figure 16. Number of VOC peaks: younger vs older (controls and subjects with 
PKU). 
 
 
Figure 17. Number of VOC peaks: male vs female (controls and subjects with 
PKU). 
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4 Discussion 
The results of this study provide an important insight into how subjects 
with PKU perceive their breath after consuming PS. The questionnaire results 
suggest that control subjects worried little or not at all about their breath, but 
subjects with PKU were concerned about breath odour and associated this 
with PS. However, the 2 types of PS were not perceived in the same way, 
since 95% of subjects with PKU stated that they notice their breath more with 
L-AA than CGMP-AA. Unlike CGMP-AA, L-AA was also associated with others 
noticing breath malodours. Study results from the questionnaire suggests that 
the effects of L-AA and CGMP-AA on exhaled breath are likely to be different, 
immediately post-consumption. The effects of PS consumption were analysed 
by locating and extracting VOC information from the headspace gas and 
breath samples for both PS.   
Analysis of headspace gas from L-AA and CGMP-AA was associated with 
over 75 and 140 VOC peaks, respectively; while only 25-30 VOC peaks were 
detected in the exhaled breath from subjects with PKU, 5 minutes after PS 
consumption. VOCs in PS thus appear in reduced numbers and lower 
concentrations in exhaled breath, shortly post-consumption. CGMP-AA is 
likely associated with greater numbers of VOC peaks, due to additional 
flavourings and sweeteners, compared with L-AA. This is reflected in the 
questionnaire results (Figure 3) regarding PS taste, as 50% of subjects with 
PKU stated they dislike or strongly dislike the taste of L-AA, compared to 35% 
with CGMP-AA. Subjectively, CGMP-AA is described to have a sweet smell 
(like ice cream) and taste less like traditional L-AA. Experiments measuring 
breath odour post-PS administration demonstrate that there is an immediate 
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and objective change to the breath content of subjects with PKU, 5 minutes 
after consuming supplements. The strong alignment of VOC peaks in both the 
headspace gas and breath suggest that for a short duration, the subject’s 
breath is perceived similarly to the PS. However, the immediacy of this intense 
taste in the mouth is likely to lead to subjective differences, since perceived 
taste and measurable difference in exhaled breath are not the same.  
Longitudinal breath testing results show that the mean number of VOC 
peaks in exhaled breath increase after the fasted breath sample, in all 3 
groups. Likewise, the initial number of VOC peaks in fasted breath are similar. 
This indicates that there is no fundamental difference in breath composition 
between controls and subjects on a low-protein diet, supplemented with PS – 
detectable using our analytical platform. Common breath compounds, such as 
acetone, 2-propanol, hexanal, 2-butanone and 1-propanol were observed in 
fasted samples, including the control group.  
The longitudinal trends of control and L-AA groups are characterised by 2 
increases in the number of measured VOC peaks; specifically, during the  
‘before midday meal’ and ‘afternoon’ samples. In the CGMP-AA group, the 
number of VOC peaks were observed to increase until the ‘after midday meal’ 
sample and decrease thereafter. The increase in exhaled VOCs following 
meals, and throughout the day generally, is partially associated with the intake 
of food and drinks. For example, limonene was observed in postprandial 
samples from both control and subjects with PKU, especially those who drank 
orange cordial. It is well known that some dietary products can leave a residual 
taste and cause transient breath odours (e.g. onions, garlic and spicy foods) 
[9]. The increase in the number of exhaled VOCs throughout the day is also 
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linked to day-time metabolic processes and the microbiome in the 
gastrointestinal tract, which generates additional VOCs during the metabolism 
of nutrients [20,21]. Subjects with PKU are not observed to have significantly 
more, or different types of VOCs in exhaled breath, when sampled 30 minutes 
after consumption of either PS.   
The headspace gas analysis enabled identification of the locations of VOC 
peaks relating to the PS. The locations of these VOCs were tracked across 
the longitudinal samples in Figure 11. However, none of the VOC peaks 
directly related to those in the headspace gas were detected in any breath 
samples from subjects with PKU, for either PS. These findings suggest that 
the effects of the PS disappear in less than 30 minutes after consumption. This 
strongly indicates that breath malodour from the supplements is reduced, or 
entirely removed, by the intervention of food and drinks. Comparing samples 
from subjects with PKU to those from controls, we did not observe any 
additional VOC peaks, which could be linked to by-products of 
pharmacokinetic effects and metabolic breakdown of the supplement.  
Analysis of possible confounding factors indicate that differences in the 
number and trends of VOCs throughout the day are more likely related to 
factors of age and gender, rather than PKU-associated effects, since the 
differences in the results from confounding factor groups are greater than in 
the intervention groups. This provides further evidence to suggest that the 
composition of breath between subject with PKU and controls is not 
fundamentally different. The trends in Figure 16 and Figure 17 are quite 
similar, which could be related to more females being recruited (22F: 18M) 
and the mean age of female subjects being marginally higher than males; 11.0 
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years (standard deviation: 2.6) and 9.8 years (standard deviation 2.2), 
respectively.  
Intensity monitoring of specific compounds, such as acetone and dimethyl 
sulphide, demonstrate similar trends across all groups. There is, however, an 
interesting difference in the concentration of 2-butanone between subjects 
with PKU and controls in the post-morning meal sample. While controls are 
associated with a gradual increase throughout the day, both L-AA and CGMP-
AA are associated with a sharp rise after their morning meal (around 3.9 ppb 
for subjects with PKU, for both PS, compared to 2.0 ppb for controls). These 
levels drop subsequently and maintain similar trends to controls for the rest of 
the day. This could be a metabolic response to the PS and requires further 
investigation. Similar peaks are not observed following the midday and 
evening meal PS, which suggests that this only occurs post-fasting. The 
quantification results for 2-butanone can be used for comparison with other 
studies or serve as a reference for future studies. Regarding dimethyl 
sulphide, the intensity trend is shown to decrease throughout the day, after the 
fasted sample. It is possible that this compound is associated with malodorous 
breath upon awakening, known as ‘morning breath’. These unpleasant odours 
are VSCs, which are produced by bacteria during sleep, as a result of 
decreased salivation (i.e. dry mouth) [22,23]. This effect usually lasts a few 
hours and can be reduced or relieved through oral hygiene (brushing of teeth) 
and/or consumption of breakfast. Findings from this study suggests that 
dimethyl sulphide concentrations in exhaled breath are similar in subjects with 
or without PKU, for both PS.  
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There are some limitations associated with this study. For example, the 
scope of this study focuses only on the PS and not on blood Phe levels. In 
future studies, blood Phe levels could be monitored in conjunction with breath 
measurements, to determine any links between exhaled breath composition 
and Phe levels. It has also been suggested that Phe could be converted to 
phenyl ketones, which may contribute to malodour [24]. This is also worth 
investigating.  
A further limitation of this study is that targeted monitoring of sulphur-
based compounds using dedicated VSC-monitors may provide insight beyond 
the generally screening approach taken here using GC-IMS technology. 
Another drawback is that only a small number of subjects (n=3) provided 
breath samples, 5 minutes after consuming the PS. While we were able to 
demonstrate that it was possible to measure the immediate effect of 
consuming L-AA and CGMP-AA PS, longitudinal breath testing using GC-IMS 
could not establish any significant and measurable changes between controls 
and subjects with PKU, for either PS.  
These findings strongly suggest that the reported effects of breath 
malodour are transient in nature and can be reduced, or completely removed, 
by the intervention of food and drinks. Further work should include an 
investigation of intervention methods to determine which are most effective at 
reducing or completely removing temporary breath malodour, following the 
consumption of L-AA or CGMP-AA. For example, a simple intervention study 
comparing the composition of exhaled breath of subjects with PKU who rinse 
their mouth with water post-consumption of PS, to those who do not.  
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5 Conclusions 
In this longitudinal cross-over pilot study, exhaled VOCs were measured 
using GC-IMS technology when subjects took both L-AA and CGMP-AA 
protein substitutes. Headspace gas from L-AA and CGMP-AA were 
associated with over 75 and 140 VOC peaks, respectively; while only 25-30 
VOC peaks were detected in the exhaled breath from subjects with PKU, 5 
minutes after consuming the PS. The strong alignment of VOC peaks in both 
headspace gas and breath suggest that consuming PS has an immediate 
impact on breath composition. Fasted L-AA and CGMP-AA breath samples 
contained a similar number of VOC peaks (10-12) as controls. Monitoring of 
specific VOCs indicate that acetone and dimethyl sulphide demonstrate similar 
trends across groups. Post-fasted samples from subjects with PKU, for both 
PS, were associated with a sharp increase in 2-butanone concentration, which 
was not observed in the control group. This should be further investigated, as 
it could be a metabolic response relating to the post-fasted consumption of 
PS. Intensity tracking of dimethyl sulphide suggests a subsiding trend of 
‘morning breath’ across all groups. Longitudinal breath testing showed that 
there were no significant differences in the number and types of exhaled VOCs 
compared to controls or between PS (12-18 VOC peaks). PS are thus shown 
to have a transient effect on exhaled breath. This indicates that any PS-related 
unpleasant breath odours are eliminated by food or drinks.   
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6 Appendix A – Staggered Breath Sampling Time 
Time Subject 1 Subject 2 Subject 3 Subject 4 
08:00 Room Air Sample 1 
08:15 Arrive Arrive Arrive Arrive 
08:30 Fasted Sample Break 
Break 
Break 08:45 
Morning Meal 
Fasted Sample 
09:00 
Morning Meal 
Fasted Sample 
09:15 
Morning Meal 
Fasted Sample 
09:30 After Morning Meal 
Morning Meal 09:45 
 
Break 
 
 
After Morning Meal 
10:00 
Break 
After Morning Meal 
10:15 
Break 
After Morning Meal 
10:30 – 10:45 Break 
11:00 Room Air Sample 2 
11:15 – 11:30 Break 
Break 
Break 
Break 
11:45 Before Midday Meal 
12:00 
Midday Meal 
Before Midday Meal 
12:15 
Midday Meal 
Before Midday Meal 
12:30 
Midday Meal 
Before Midday Meal 
12:45 After Midday Meal 
Midday Meal 13:00 
Break 
After Midday Meal 
13:15 
Break 
After Midday Meal 
13:30 
Break 
After Midday Meal 
13:45 
Break 
14:00 Afternoon Sample 
14:15 
Break 
Afternoon Sample 
14:30 
Break 
Afternoon Sample 
14:45 
Break 
Afternoon Sample 
15:00 Break 
15:15 Room Air Sample 3 
15:30 – 16:15 Break 
Break 
Break 
Break 
16:30 
Before Evening 
Meal 
16:45 
Evening Meal 
Before Evening 
Meal 
17:00 
Evening Meal 
Before Evening 
Meal 
17.15 
Evening Meal 
Before Evening 
Meal 
17.30 After Evening Meal 
Evening Meal 17.45 
Finished 
After Evening Meal 
18.00 
Finished 
After Evening Meal 
18.15 
Finished 
After Evening Meal 
18.30 Finished 
18.45 Room Air Sample 4 
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